1. Home
  2. NVCR vs PAR Comparison

NVCR vs PAR Comparison

Compare NVCR & PAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • PAR
  • Stock Information
  • Founded
  • NVCR 2000
  • PAR 1968
  • Country
  • NVCR Jersey
  • PAR United States
  • Employees
  • NVCR N/A
  • PAR N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • PAR Office Equipment/Supplies/Services
  • Sector
  • NVCR Health Care
  • PAR Miscellaneous
  • Exchange
  • NVCR Nasdaq
  • PAR Nasdaq
  • Market Cap
  • NVCR 3.0B
  • PAR 2.8B
  • IPO Year
  • NVCR 2015
  • PAR N/A
  • Fundamental
  • Price
  • NVCR $30.97
  • PAR $73.51
  • Analyst Decision
  • NVCR Buy
  • PAR Strong Buy
  • Analyst Count
  • NVCR 5
  • PAR 8
  • Target Price
  • NVCR $33.40
  • PAR $79.25
  • AVG Volume (30 Days)
  • NVCR 1.9M
  • PAR 472.7K
  • Earning Date
  • NVCR 10-30-2024
  • PAR 11-08-2024
  • Dividend Yield
  • NVCR N/A
  • PAR N/A
  • EPS Growth
  • NVCR N/A
  • PAR N/A
  • EPS
  • NVCR N/A
  • PAR N/A
  • Revenue
  • NVCR $577,738,000.00
  • PAR $453,986,000.00
  • Revenue This Year
  • NVCR $19.13
  • PAR N/A
  • Revenue Next Year
  • NVCR $5.38
  • PAR $19.03
  • P/E Ratio
  • NVCR N/A
  • PAR N/A
  • Revenue Growth
  • NVCR 14.63
  • PAR 49.11
  • 52 Week Low
  • NVCR $11.70
  • PAR $37.74
  • 52 Week High
  • NVCR $34.13
  • PAR $82.24
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 60.66
  • PAR 47.19
  • Support Level
  • NVCR $29.85
  • PAR $75.59
  • Resistance Level
  • NVCR $34.13
  • PAR $77.22
  • Average True Range (ATR)
  • NVCR 2.00
  • PAR 2.49
  • MACD
  • NVCR -0.33
  • PAR -0.99
  • Stochastic Oscillator
  • NVCR 44.92
  • PAR 7.61

About NVCR NovoCure Limited

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About PAR PAR Technology Corporation

PAR Technology Corp together with its subsidiaries provides management technology solutions including software, hardware, and related services, integral to the point-of-sale infrastructure and task management, information gathering, assimilation, and communication services. It has two segments. The restaurant/ Retail segment provides point-of-sale and management technology solutions such as hardware, software, and integrated technical solutions to the restaurant and retail industries. The government segment provides intelligence, surveillance, and reconnaissance solutions and mission systems support. The company derives the majority of its revenues from the Restaurant/ Retail segment.

Share on Social Networks: